Kiromic BioPharma, Inc. (KRBP)

Kiromic BioPharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019	2018
Net Income	-20.95	-38.18	-25.65	-19.2	-3.75	Upgrade
Depreciation & Amortization	2.22	1.67	0.47	0.2	0.09	Upgrade
Share-Based Compensation	0.14	1.24	3.76	13.25	0.52	Upgrade
Other Operating Activities	-2.64	11.52	1.1	-0.37	0.23	Upgrade
Operating Cash Flow	-21.23	-23.75	-20.32	-6.13	-2.91	Upgrade
Capital Expenditures	-0.21	-4.88	-1.89	-1.46	-0.3	Upgrade
Acquisitions	0	0	0.08	0	0	Upgrade
Other Investing Activities	-	0.02	-	-	-	Upgrade
Investing Cash Flow	-0.21	-4.87	-1.81	-1.46	-0.3	Upgrade
Common Stock Issued	0.66	0	40	15	0	Upgrade
Other Financing Activities	23.33	3.9	-2.66	0.81	4.76	Upgrade
Financing Cash Flow	23.99	3.9	37.34	15.81	4.76	Upgrade
Net Cash Flow	2.56	-24.71	15.2	8.22	1.54	Upgrade
Free Cash Flow	-21.43	-28.63	-22.22	-7.58	-3.22	Upgrade
Free Cash Flow Per Share	-19.53	-52.57	-58.37	-50.50	-24.87	Upgrade

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.